What is Neoproteomics?
Founded in 2006 and headquartered in Moreland Hills, Ohio, Neoproteomics operates as a specialized provider of structural mass spectrometry and hydroxyl radical protein footprinting services. The company occupies a critical niche in the biotechnology sector, offering high-precision solutions for protein-based pharmaceuticals. Their core competencies include protein drug interaction mapping, epitope mapping, and integrated structural biological services, which are essential for modern drug discovery pipelines. By providing affordable and efficient analytical insights, Neoproteomics enables biotech firms to accelerate their research and development cycles, effectively bridging the gap between complex protein analysis and therapeutic application.
How much funding has Neoproteomics raised?
Neoproteomics has raised a total of $28K across 1 funding round:
Debt
$28K
Debt (2021): $28K with participation from PPP
Key Investors in Neoproteomics
PPP
Public-Private Partnership
What's next for Neoproteomics?
With the recent influx of capital, Neoproteomics is poised to enter a new phase of operational maturity. The strategic focus will likely shift toward expanding its laboratory infrastructure and increasing the throughput of its structural biology services to meet the rising demand for protein-based drug development. As the company navigates this growth trajectory, it will continue to refine its footprinting technologies, potentially exploring new partnerships within the pharmaceutical industry to solidify its market leadership. The firm's ability to maintain high-quality, cost-effective research services will be the primary driver of its long-term competitive advantage in the evolving proteomics landscape.
See full Neoproteomics company page
